Posts by Philip Dooner

Call for papers: Infectious Agents & Cancer announces series on Burkitt Lymphoma

Philip Dooner on February 7, 2013 at 9:55 am - 0 Comments

Franco M Buonaguro and Sam M Mbulaiteye, Editors-in-Chief of Infectious Agents & Cancer, would like to invite you to submit your manuscript to a new thematic series, entitled “Burkitt Lymphoma, Beyond Discoveries” which will be published in the journal.

Burkitt Lymphoma (BL) is an aggressive non-Hodgkin lymphoma (NHL) that was first described by Dennis Burkitt in 1958 in Ugandan children. Since then, numerous breakthroughs, including the discovery of the Epstein-Barr virus (EBV), and its links to the disease, have been made. The most important of these discoveries has been the demonstration of curability of lymphoma which has re-invigorated efforts to use chemotherapy to treat cancer and helped establish some of the key principles of chemotherapy for …

Nominations for BioMed Central’s Research Awards close soon

Philip Dooner on January 23, 2013 at 3:26 pm - 0 Comments

The deadline to recommend an article for the BioMed Central Research Awards is fast approaching, with nominations closing on the 31st January.

Now in its 7th year, the awards will celebrate the best research published across BioMed Central’s portfolio of more than 240 open access journals in 2012. There are 10 refined categories covering all areas of Biology, Medicine and Health services research, as well as dedicated prizes for case reports, open data and advocacy, The awards this year will allow us to distinguish the articles that deserve recognition across several disciplines.

Each category will be overseen by a dedicated judging panel of internationally recognised leaders in …

Immunotherapy goes broad at BioMed Central

Philip Dooner on January 10, 2013 at 10:32 am - 0 Comments

In September 2009, Journal of Translational Medicine (JTM) and the then International Society for the Biological Therapy of Cancer (iSBTc) launched the Tumor Immunology and Biological Cancer Therapy section in the journal and with it JTM became a venue for the discussion of hot issues in tumor immunology which were highly relevant to translating novel immune interventions. Launched at a turning point in cancer immunotherapy, when considerable advances in understanding the relationship between the immune system and cancer started to translate to pioneering active immunotherapies, the section and journal quickly grew under the guidance of Section Editor Pedro Romero, and the renamed Society for ImmunoTherapy of Cancer (SITC), to become a …

Nutritional supplements for diabetes prevention: hype or hope?

Philip Dooner on October 8, 2012 at 8:44 am - 0 Comments

Predictive, preventive and personalized medicine (PPPM) is positioned as one of the key components to the future of patient care. As outlined in an editorial The EPMA Journal, which recently moved from Springer to BioMed Central, aims to promote this paradigm change “from delayed interventional ‘disease care’ to PPPM as the medicine of the future” by disseminating reviews that cover at least two of the three aspects of PPPM.
One such recently published review article discusses the commonly-held belief that the nutritional supplement chromium picolinate (CrPic) is of benefit in the treatment of type 2 diabetic, obese and diabetes predisposed individuals. But as one of the authors and Editor-in-Chief, Olga Golubnitschaja, explains: …

New cancer syndrome published in Journal of Translational Medicine

Philip Dooner on August 30, 2012 at 3:53 pm - 0 Comments

New research published in the Journal of Translational Medicine’s Personalized medicine section outlines the discovery that germ line BAP1 defects are responsible for a novel cancer syndrome characterised by malignant mesothelioma, uveal melanoma, cutaneous melanoma and atypical melanocytic tumors, known as “melanocytic BAP1-mutated atypical intradermal tumors” (MBAITs).

Researchers from the University of Hawai‘i Cancer Center investigated two families with BAP1 defects and found an increase in the occurrence of mole-like melanocytic lesions and were able to determine that these benign tumors carried BAP1 mutations. The article concludes that the presence of melanocytic tumors can be used as a visual marker for identifying individuals with germ line BAP1 mutations and, as a result, are at higher risk of …

BioMed Central launches two more journals from Tehran University of Medical Sciences

Philip Dooner on August 2, 2012 at 3:35 am - 0 Comments

Following
the launch of DARU Journal of
Pharmaceutical Sciences last month, BioMed Central is pleased to add two
more journals from the Tehran University of Medical Sciences (TUMS) to its
portfolio. Journal of Diabetes & Metabolic Disorders and Iranian Journal of Environmental Health Science & Engineering have now published their first articles with us.

Journal
of Diabetes & Metabolic Disorders provides a forum for scientific
inquiry of the highest standard in the fields of diabetes and metabolic
disorders. As well as an editorial by
Editor-in-Chief Bagher Larijani, the inaugural articles include original research on the Anti-inflammatory effect of insulin in
rabbits with hypercholesterolemia as well as an …

DARU journal of Pharmaceutical Sciences launches with BioMed Central

Philip Dooner on July 19, 2012 at 2:59 am - 0 Comments

DARU Journal of Pharmaceutical Sciences has published its
inaugural articles with BioMed Central. Amongst these are an editorial by Editor-in-Chief Mohammad Abdollahi
which highlights the need for a quality, open-access journal in the field of
pharmaceutical sciences. The launch
articles also include original research on enhancing indomethacin release in vitro, and propylene glycol tolerance
in neonates, as well as a review article on the status of lead pollution and
toxicity in Iran.

The word ‘DARU’ is derived from
the Persian name for drug and the journal aims to act as a platform for all
areas of drug conception, design, manufacture, classification and
assessment. The journal is …

BioMed Central attends the AACR Annual Meeting

Philip Dooner on April 24, 2012 at 9:25 am - 0 Comments

Between the 31st March and the 4th
April 2012, BioMed Central attended the Annual
Meeting of the American Association for
Cancer Research (AACR),the
oldest and largest cancer research organization in the world, in Chicago,
Illinois. The theme of this year’s meeting was “Accelerating Science:
Concept to Clinic” and more than 16,000 attendees were treated to talks
covering all aspect of basic, translational and clinical cancer research.
The AACR conference was an ideal showcase for BioMed Central’s portfolio of Cancer journals, which
includes Breast Cancer Research,
Molecular Cancer and BMC Cancer, along with BMC
Medicine, the flagship medical journal of the BMC-series.

We were delighted to meet Francesco Marincola,
Editor-in-Chief of …

Experimental Hematology & Oncology is now publishing

Philip Dooner on March 26, 2012 at 5:17 am - 0 Comments

Experimental Hematology & Oncology has published its
inaugural articles. Amongst these are an
editorial by Editors-in-Chief Zihai Li and Delong Liu, and Deputy Editor
Chung-Tsen Hsueh which highlights the need for the publication of negative
research results. The launch articles
also include original research on the effectiveness of oxidative stress and
redox regulating enzymes in diffuse large B-cell lymphoma prognosis.

Experimental Hematology & Oncology is an open access,
peer-reviewed online journal that encompasses all aspects of hematology and
oncology with emphasis on preclinical, basic, patient-oriented and
translational research. The journal acts as an international platform for
sharing laboratory findings in these areas and makes a deliberate effort to
publish clinical trials with "negative" results …

Experimental Hematology & Oncology is now accepting submissions

Philip Dooner on February 29, 2012 at 2:48 am - 0 Comments

Experimental Hematology & Oncology is now accepting submissions. The journal will make a deliberate effort in publishing clinical trials with "negative" results and basic science studies with provocative findings.

“Experimental Hematology & Oncology aims to publish original work, hypothesis, commentaries and timely reviews in the field of hematology and oncology”, says co-Editor-in-Chief Delong Liu. “With open access, rapid turnaround time from submission to publication and online live comments from readers, Experimental Hematology & Oncology will strive to be the hub for disseminating new knowledge and discussing controversial topics for both basic scientists and busy clinicians in the field of hematology and oncology.”

Hematology and oncology are closely related and rapidly changing fields. The journal acts as an international platform for sharing …